---
title: "Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/000661.SZ.md"
symbol: "000661.SZ"
name: "Changchun High-Tech Industry (Group) Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-19T22:52:54.238Z"
locales:
  - [en](https://longbridge.com/en/quote/000661.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/000661.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/000661.SZ.md)
---

# Changchun High-Tech Industry (Group) Co., Ltd. (000661.SZ)

## Company Overview

Changchun High-Tech Industry (Group) Co., Ltd., together with its subsidiaries, researches, develops, manufactures, and sells biopharmaceuticals and traditional Chinese medicines products in China. The company offers recombinant human growth hormone injection; recombinant human follicle stimulating hormone for injection; herpes zoster vaccines; live attenuated varicella vaccine; freeze-dried nasal spray live attenuated influenza; xueshuanxinmaining tablet; and yinhuamiyanling tablet. It also develops real estate properties. The company was founded in 1993 and is based in Changchun, China.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.ccht.jl.cn](https://www.ccht.jl.cn) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:08.000Z

**Overall: C (0.60)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 70 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -12.14% |  |
| Net Profit YoY | -101.91% |  |
| P/B Ratio | 1.51 |  |
| Dividend Ratio | 3.10% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 33671614437.13 |  |
| Revenue | 11661773801.90 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -0.18% | D |
| Profit Margin | -0.36% | D |
| Gross Margin | 77.95% | A |
| Revenue YoY | -12.14% | E |
| Net Profit YoY | -101.91% | E |
| Total Assets YoY | -2.93% | D |
| Net Assets YoY | -5.37% | D |
| Cash Flow Margin | -3165.08% | E |
| OCF YoY | -12.14% | E |
| Turnover | 0.37 | C |
| Gearing Ratio | 18.30% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Changchun High-Tech Industry (Group) Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-12.14%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-101.91%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "1.51",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "3.10%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "33671614437.13",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "11661773801.90",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "-0.18%",
          "rating": "D"
        },
        {
          "name": "Profit Margin",
          "value": "-0.36%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "77.95%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "-12.14%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-101.91%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-2.93%",
          "rating": "D"
        },
        {
          "name": "Net Assets YoY",
          "value": "-5.37%",
          "rating": "D"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-3165.08%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "-12.14%",
          "rating": "E"
        },
        {
          "name": "Turnover",
          "value": "0.37",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "18.30%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -810.03 | 219/215 | 40.81 | 36.02 | 19.41 |
| PB | 1.53 | 46/215 | 1.88 | 1.76 | 1.59 |
| PS (TTM) | 2.91 | 73/215 | 3.34 | 3.13 | 2.91 |
| Dividend Yield | 3.07% | 30/215 | 2.91% | 2.58% | 2.35% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-28T16:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 4 | 80% |
| Overweight | 1 | 20% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 83.38 |
| Highest Target | 111.34 |
| Lowest Target | 111.34 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/000661.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/000661.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/000661.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/000661.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**